Quintiles recently allied with XenoTech, LLC for their “drug metabolism services” (see link below to ISSX 2003). XenoTech recently raised the bar of their drug metabolism services by signing an exclusive agreement with MultiCell Technologies (parent company is Exten Industries (Symbol: EXTI) for their proprietary human liver cell lines for preclinical drug testing. These cells are created in a laboratory and are highly metabolic and supposedly retain their properties longer than any previously available human liver cells.
12th North American ISSX Meeting
Providence, Rhode Island Oct 12 -16 2003
This is from the program:
Quintiles Nasdaq (Symbol QTRN)
"Through our recent alliance with Xenotech, LLC in Lenexa, KS, Quintiles in North America now offers an unmatched combination of expertise in in vitro, in vivo and ex vivo drug metabolism services. This compliments and re-inforces our existing in vitro metabolism services offered from our European facility in Edinburgh, UK."
XenoTech
XenoTech offers an extensive selection of premier quality products in support of drug metabolism and hepatotoxicity [liver] research; we consistently meet or surpass our customers’ expectations for cryopreserved human and non-human hepatocytes, hepatic and extra-hepatic fractions from many differentspecies, rCYP enzymes, antibodies to drug metabolizing enzymes and their peptides, and we now offer a new, breakthrough product, immortalized human hepatocytes [human liver cells].
XenoTech has long enjoyed a reputation for impeccably-executed studies, and we recently added new systems and capacity to speed up delivery of those same excellent results to all phases of candidate selection and development. Our study designs closely conform to the recommendations of the Basel Consensus Conference on Optimizing Drug Development, and the recent publication of the PhRMA Perspective on Conduct of Drug Interaction Studies.
We are the exclusive North American source of MultiCell’s immortalized human hepatocytes used for both in-house analyses at drug companies and for contract studies at XenoTech,, as well as Bactosome rCYPs from Cypex in Dundee, U.K. A recent strategic alliance with Quintiles Transnational in Kansas City, means that scientists can benefit from an unmatched combination of expertise, speed, and convenience in preclinical, and even post-clinical, in-vitro, in-vivo, and ex-vivo studies.
issx.org
So, if Quintiles likes XenoTech for their “drug metabolism services”…….and XenoTech likes MultiCell for their human liver cells for preclinical testing (drug interactions) …then maybe some of you here might like EXTI, too! Take a look and see. Worth it IMO! |
